93349-99-6

Usage

Uses

Used in Pharmaceutical Industry:
5-Bromo-6-methoxynicotinic acid methyl ester is used as a building block for the synthesis of various drugs and biologically active molecules. Its unique chemical structure allows it to undergo a wide range of chemical reactions, enabling the production of novel compounds with potential therapeutic properties.
Used in Organic Synthesis:
In the field of organic synthesis, 5-Bromo-6-methoxynicotinic acid methyl ester is employed as a versatile intermediate. Its reactivity and ability to participate in various chemical transformations make it a valuable component in the synthesis of complex organic molecules.
Used in Medicinal Chemistry:
5-Bromo-6-methoxynicotinic acid methyl ester serves as a key component in medicinal chemistry, where it is utilized for the development of new drugs and pharmaceuticals. Its unique chemical properties and reactivity contribute to the discovery and optimization of novel therapeutic agents.
Used in Research and Development:
As a valuable research tool, 5-Bromo-6-methoxynicotinic acid methyl ester is employed in the exploration of new drug candidates and the advancement of pharmaceutical formulations. Its unique structure and reactivity facilitate the investigation of its potential applications in various therapeutic areas.

InChI:InChI=1/C8H8BrNO3/c1-12-7-6(9)3-5(4-10-7)8(11)13-2/h3-4H,1-2H3

Upstream product

• 381247-99-0 methyl 5-bromo-6-oxo-1,6-dihydropyridine-3-carboxylate 
• 29241-62-1 5-bromo-6-chloronicotinic acid 
• 5006-66-6 6-hydroxy-3-pyridinecarboxylic acid 
• 124-41-4 sodium methylate 
• 381247-99-0 methyl 5-bromo-6-hydroxypyridine-3-carboxylate 
• 41668-13-7 5-bromo-6-hydroxy-3-pyridinecarboxylic acid 
• 1190862-68-0 ethyl 5,6-dibromonicotinate 
• 5006-66-6 6-hydroxynicotinic acid 
• 78686-77-8 5-bromo-6-chloro-3-pyridinecarboxylic acid methyl ester 

Downstream Products

• 234107-97-2 methyl 6-methoxy-5-methylnicotinate 
• 93350-03-9 Methyl 5-Phenyl-6-methoxynicotinate 
• 93350-05-1 Methyl 5-(2-Methoxyphenyl)-6-methoxynicotinate 

Relevant academic research and scientific papers

PYRAZOLYL-SUBSTITUTED PYRIDONE COMPOUNDS AS SERINE PROTEASE INHIBITORS

There are provided inter alia pyrazolyl-substituted pyridone compounds, which exhibit biological activity, e.g., inhibitory action, against serine proteases, including thrombin and various kallikreins. There are additionally provided pharmaceutical compositions. There are additionally provided methods of treating and preventing certain diseases or disorders, which disease or disorder is amenable to treatment or prevention by the inhibition of serine proteases, including thrombin and various kallikreins.

Design and structural analysis of aromatic inhibitors of type II dehydroquinase from mycobacterium tuberculosis

3-Dehydroquinase, the third enzyme in the shikimate pathway, is a potential target for drugs against tuberculosis. Whilst a number of potent inhibitors of the Mycobacterium tuberculosis enzyme based on a 3-dehydroquinate core have been identified, they generally show little or no in vivo activity, and were synthetically complex to prepare. This report describes studies to develop tractable and drug-like aromatic analogues of the most potent inhibitors. A range of carbon-carbon linked biaryl analogues were prepared to investigate the effect of hydrogen bond acceptor and donor patterns on inhibition. These exhibited inhibitory activity in the high-micromolar range. The addition of flexible linkers in the compounds led to the identification of more potent 3-nitrobenzylgallate- and 5-aminoiso-phthalate-based analogues.

AROMATIC RING COMPOUND

Provided is an aromatic ring compound having a GPR40 agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity, and is useful as an agent for the prophylaxis or treatment of diabetes and the like.

CYCLOALKENYL ARYL DERIVATIVES FOR CETP INHIBITOR

The present invention relates to cycloalkenyl aryl derivatives, isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof, or solvates thereof; a method for preparing the derivatives; and pharmaceutical compositions containing the same.

SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS

The present invention relates to compounds described herein Formula (I) and pharmaceutical acceptable salts thereof, which modulate the activity of calcium release- activated calcium (CRAC) channel. The invention also describes the compounds of Formula (I)and pharmaceutical compositions containing such compounds thereof for treating, managing, and/or lessening the severity of diseases, disorders, syndromes or conditions associated with the modulation of calcium release-activated calcium (CRAC) channel.

HYDROXAMIC ACID DERIVATIVES AS GRAM-NEGATIVE ANTIBACTERIAL AGENTS

The invention relates to chemical compounds of formula (IB): or a salt thereof. In some embodiments, the invention relates to inhibitors of UDP-3-0 — (R-S-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC). In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein and their use in the prevention and/or treatment of Gram- negative bacterial infections.

A General Synthesis of 5-Arylnicotinates

Arylboronic acids have been found to couple efficiently with 5-bromonicotinates to yield 5-arylnicotinates.The reaction is considerably more sensitive to steric inhibition in the arylboronic acid component than in the pyridyl bromide 4.The dianion salt of the boronic acid is implicated as the reactive intermediate responsible for the facile coupling reaction.Pure arylboronic acids are best prepared by using triisopropyl borate as the transmetalating agent.